GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

The ruling will affect GSK’s Arexvy and Pfizer’s Abrysvo, both of which were approved by the agency in May of 2023 for adults 60 years or older and realized booming sales in their first year ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

The risks flagged in the prescribing information of GSK's Arexvy and Pfizer's Abrysvo were not the regulator's strictest "boxed" warnings. GBS is a rare disorder in which the body's immune system ...

The FDA identified an estimated 9 excess GBS cases per million doses for Pfizer's Abrysvo and 7 excess cases per million for GSK's Arexvy. Updated warnings stem from Medicare-based studies ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

GSK plc (NYSE:GSK) is advancing several promising ... Shares were also aided by a successful US and European launch of Arexvy, a respiratory syncytial virus (RSV) vaccine for older adults.

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...